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Abstract
Background.—The epidemiology of Mycoplasma pneumoniae (Mp) among US children (<18 
years) hospitalized with community-acquired pneumonia (CAP) is poorly understood.
Methods.—In the Etiology of Pneumonia in the Community study, we prospectively enrolled 
2254 children hospitalized with radiographically confirmed pneumonia from January 2010-June 
2012 and tested nasopharyngeal/oropharyngeal swabs for Mp using real-time polymerase chain 
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reaction (PCR). Clinical and epidemiological features of Mp PCR–positive and –negative children 
were compared using logistic regression. Macrolide susceptibility was assessed by genotyping 
isolates.
Results.—One hundred and eighty two (8%) children were Mp PCR-positive (median age, 7 
years); 12% required intensive care and 26% had pleural effusion. No in-hospital deaths occurred. 
Macrolide resistance was found in 4% (6/169) isolates. Of 178 (98%) Mp PCR–positive children 
tested for copathogens, 50 (28%) had ≥1 copathogen detected. Variables significantly associated 
with higher odds of Mp detection included age (10–17 years: adjusted odds ratio [aOR], 10.7 
[95% confidence interval {CI}, 5.4–21.1] and 5–9 years: aOR, 6.4 [95% CI, 3.4–12.1] vs 2–4 
years), outpatient antibiotics ≤5 days preadmission (aOR, 2.3 [95% CI, 1.5–3.5]), and copathogen 
detection (aOR, 2.1 [95% CI, 1.3–3.3]). Clinical characteristics were non-specific.
Conclusions.—Usually considered as a mild respiratory infection, Mp was the most commonly 
detected bacteria among children aged ≥5 years hospitalized with CAP, one-quarter of whom had 
codetections. Although associated with clinically nonspecific symptoms, there was a need for 
intensive care in some cases. Mycoplasma pneumoniae should be included in the differential 
diagnosis for school-aged children hospitalized with CAP.
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Mycoplasma pneumoniae is a common bacterial pathogen associated with a wide array of 
clinical manifestations, including upper respiratory infections, pneumonia, and 
extrapulmonary manifestations (eg, encephalitis, Stevens-Johnson syndrome) [1–7]. 
Mycoplasma pneumoniae (Mp) is also often associated with community- and facility-based 
outbreaks, particularly among school-aged children and young adults [8–13]. However, the 
burden and epidemiology of hospitalized community-acquired pneumonia (CAP) due to Mp 
is poorly understood, largely because diagnostic testing has generally employed serology or 
nonstandardized molecular approaches [14].
The Centers for Disease Control and Prevention’s (CDC) Etiology of Pneumonia in the 
Community (EPIC) study was a prospective, multicenter, active population-based 
surveillance study of the incidence and etiology of CAP among hospitalized US patients. In 
the EPIC study, Mp was the most commonly detected bacterial pathogen (8%) among 
enrolled children (<18 years old), with an estimated annual incidence of 1.4 (95% 
confidence interval [CI], 1.2–1.6) cases per 10 000 children using real-time polymerase 
chain reaction (PCR) [15]. Using this dataset, we describe the specific epidemiological and 
clinical features of Mp CAP among hospitalized children.
METHODS
Study Population
The details of the pediatric EPIC study have been published else where [15]. In brief, 
children (<18 years of age) admitted with clinical and radiographic pneumonia were 
enrolled from 1 January 2010 through 30 June 2012, at 3 children’s hospitals (Memphis, 
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Tennessee; Nashville, Tennessee; and Salt Lake City, Utah). Final determination of inclusion 
in the study required independent confirmation by a dedicated board-certified pediatric study 
radiologist [15]. Radiographic evidence of pneumonia was defined as the presence of 
consolidation, other infiltrate, or pleural effusion [16].
Children with recent hospitalization, previous enrollment in the EPIC study, residence in an 
extended-care facility, an alternative respiratory disorder diagnosis, or newborns who never 
left the hospital were excluded, as were children with a tracheostomy, cystic fibrosis, 
neutropenia with cancer, recent solid organ or hematopoietic stem cell transplant, current 
graft-vs-host disease, or human immunodeficiency virus infection with a CD4 count <200 
cells/μL. After written informed consent, patients and/or caregivers were interviewed, and 
medical charts were abstracted for clinical and epidemiological data. Institutional review 
boards at each institution and the CDC approved the study protocol.
Specimen Collection and Laboratory Testing
Blood and respiratory specimens were obtained for pathogen testing using multiple 
modalities as previously described (Supplementary Materials) [16]. In brief, real-time PCR 
assays were performed at the study sites on combined nasopharyngeal/oropharyngeal 
(NP/OP) swabs [16]. Further Mp confirmatory testing using a multiplex real-time PCR assay 
was performed at CDC; cultures were performed on Mp PCR-positive specimens [17]. 
Macrolide susceptibility testing was performed on all corresponding isolates of Mp PCR-
positive specimens and/ or extracted nucleic acid by genotyping of the 23S ribosomal RNA 
gene using a real-time PCR assay with high-resolution melt analysis [18–21]. The Mp 
research test results were not available to treating clinicians.
Case Definitions
A CAP patient with a positive Mp PCR NP/OP specimen was considered to have Mp CAP 
(Mp PCR-positive). If Mp was not detected by PCR on a NP/OP specimen, the patient was 
considered to have CAP without Mp (Mp PCR-negative). A CAP patient was considered to 
have macrolide-resistant Mp if they had an Mp isolate and/or extracted nucleic acid with 
positive genotyping for macrolide nonsusceptibility. Codetection was defined as detection of 
Mp with ≥1 other bacterial or viral pathogen.
We also perfomed a subanalysis comparing Mp PCR-positive pneumonia to typical bacterial 
CAP (ie, detection of Haemophilus influenzae or other gram-negative bacteria, 
Staphylococcus aureus, Streptococcus anginosus, Streptococcus mitis, Streptococcus 
pneumoniae, or Streptococcus pyogenes in blood, endotracheal aspirate, bronchoalveolar 
lavage specimen, or pleural fluid using culture and/or PCR; Supplementary Materials). If 
viruses such as such as adenovirus (AdV); corona-viruses; human metapneumovirus 
(HMPV); human rhinovirus; influenza A/B viruses; parainfluenza virus (PIV) 1, 2, and 3; or 
respiratory syncytial virus (RSV) were detected by PCR of NP/ OP swabs or if serology for 
AdV, HMPV, influenza A/B, PIV, or RSV showed a 4-fold increase in antibody titer, the 
patient was considered to have viral CAP (Supplementary Materials).
Antibiotics considered active against Mp included macrolides (eg, erythromycin, 
azithromycin, and clarithromycin), fluoroquinolones (eg, levofloxacin and moxifloxacin), 
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and doxycycline. Any previous outpatient antibiotic exposure was defined as self-reported 
antibiotic use ≤5 calendar days before admission. Inpatient antibiotic exposure was defined 
as receipt of an antibiotic at any time after admission.
Statistical Analysis
We compared children hospitalized with CAP with and with-out PCR-positive Mp using 
descriptive statistics, including the Pearson χ2 or Fisher exact tests for comparison of 
categorical variables and median and interquartile ranges (IQR) for continuous data using 
nonparametric tests, as appropriate. To assess the impact of whether including children 
without a detected pathogen (n = 395 [19%]) in the Mp PCR-negative group (n = 2072) 
would impact our findings, a sensitivity analysis was performed; no significant differences 
were identified and therefore children without a detected pathogen were included in the Mp 
PCR-negative group.
We performed bivariate analyses comparing children with and without PCR-positive Mp, 
and also stratified by age; we assessed demographics and clinical features, including illness 
severity as assessed by intensive care unit (ICU) admission, invasive mechanical ventilation, 
acute respiratory distress syndrome, prolonged length of hospital stay (defined as >90th 
percentile, ie, ≥6 days), hypoxia, and death. Hypoxia was defined as oxygen saturation rate 
on admission <92% using pulse oximetry on room air, or use of supplemental oxygen at 
presentation. For children <5 years old, white blood cell (WBC) count >15 000 cells/μL or 
<5500 cells/μL, and for children ≥5 years old, WBC count >11 000 cells/μL or <3000 cells/
μL, was considered abnormal. We also performed stratified analyses assessing Mp CAP by 
antibiotic status and type, and codetected pathogens; and made specific comparisons 
between Mp CAP and CAP due to typical bacterial and respiratory viral pathogens.
We used multivariable logistic regression to assess features independently associated with 
and without positive Mp PCR; only children who had specimens tested for both bacteria and 
viruses were included. Variables with a bivariate P value <.20 or with known or 
hypothesized biological and/or epidemiological plausibility were included in the models. We 
fitted models using all candidate variables and automated stepwise procedures, and then 
fitted alternate models using only selected variables. We used Akaike information criterion 
to help select among alternate models—this statistic simultaneously accounts for goodness 
of fit and complexity of the tentative models. To resolve collinearity between study site and 
race in the final model, we controlled for study site and not race. All statistical tests were 
interpreted in a 2-tailed fashion to estimate P values and 95% confidence intervals (CIs). All 
statistical analyses were conducted using SAS version 9.3 software (SAS Institute, Cary, 
North Carolina).
RESULTS
Study Population
Among 3803 eligible children hospitalized with CAP, 2638 (69%) were enrolled; of these, 
2358 (89%) met the criteria of radiographic pneumonia. Of the 2358 children with CAP, 
2254 (96%) had Mp PCR tests performed and Mp was detected in 182 (8%). The median 
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age of Mp PCR-positive children was 7 years (IQR, 4.0–11.0 years); 60% were male and 
62% were white (Table 1). Mp was more prevalent among children aged 5–9 years (17%) 
and 10–17 years (24%) compared with children <5 years old (3%; P <.01). The highest 
prevalence of Mp was in Salt Lake City (11%), followed by Memphis (7%) and Nashville 
(6%) (Supplementary Table 1). At the Salt Lake City site, Mp was detected throughout the 
year in 2011, with no clear seasonality (Figure 1). At the other sites, peaks in summer and 
fall seasons were observed.
Bivariate and Stratified Analysis
Clinical Characteristics—The duration of symptoms before hospitalization was longer 
for Mp PCR-positive children compared with Mp PCR-negative children (median, 6.8 [IQR, 
4.6–9.5] days vs 3.6 [IQR, 2.0–5.8] days; P <.01). The differences in clinical manifestations 
between Mp PCR-positive and Mp PCR-negative children are detailed in Table 2. On chest 
radiography, Mp PCR-positive children were as likely as Mp PCR-negative children to have 
consolidation (59% vs 59%; P =.9) and multilobar infiltrates (23% vs 28%; P =.2), but more 
likely to have pleural effusion (26% vs 12%; P <.01) and hilar lymphadenopathy (10% vs 
6%; P =.02). Leukopenia was less common among Mp PCR-positive children than Mp PCR-
negative children (1% vs 6%; P =.03).
Mp PCR-positive children were less likely to require ICU admission (12% vs 21%; P <.01) 
or invasive mechanical ventilation (2% vs 7%; P <.01) than Mp PCR-negative children 
(Table 2). Among the 21 (12%) Mp PCR-positive children admitted to the ICU, age ranged 
from 4 months to 17 years (median, 6 years). Of the 3 children who required invasive 
mechanical ventilation, the 2 younger children had underlying asthma, radiographic 
consolidation, and codetections (8-month-old with RSV and rhinovirus and a 3-year-old 
with rhinovirus); an older child (9 years) had congenital heart disease, a past history of 
leukemia, alveolar disease on chest radiography, and no codetections.
When comparing children with Mp PCR-positive CAP with CAP due to typical bacterial 
pathogens, children with typical bacterial pathogens were significantly more likely to be <5 
years old (58% vs 20%; P <.01) and less likely to have rales (39% vs 63%; P <.01). Mp 
PCR-positive children were less likely to have consolidation (56% vs 81%; P < .01), pleural 
effusion (26% vs 56%; P <.01), or ICU admission (11% vs 36%; P <.01) and had a shorter 
hospital length of stay (median, 2 days vs 6 days; P <.01) than children with typical bacterial 
pneumonia (Supplementary Table 3). Compared with children with viral pneumonia, Mp 
PCR-positive children were significantly more likely to report a headache (48% vs 17%; P 
<.01) or sore throat (48% vs 26%; P <.01) but less likely to report dyspnea (61% vs 72%; P 
<.01) or rhinorrhea (3% vs 10%; P = .02). In addition, Mp PCR-positive children were less 
likely to have wheezing (25% vs 46%; P < .01) and to have ICU admission (11% vs 21%; P 
< .01) than children with viral pneumonia (Supplementary Table 3).
Antibiotic Treatment
A higher proportion of Mp PCR-positive children received an antibiotic within 5 days before 
admission compared with Mp PCR-negative children (35% vs 16%; P <.01) (Table 2). When 
stratified by age, Mp PCR-positive children were more likely to have received outpatient 
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antibiotic treatment than Mp PCR-negative children in both the 5–9 years (39% vs 16%; P <.
01) and 10–17 years (44% vs 20%; P <.01) age groups, but were as likely in those <5 years 
old (19% vs 16%). Among Mp PCR-positive children, there were no significant differences 
in outcomes (ie, ICU admission or invasive mechanical ventilation) between children who 
received outpatient antibiotics with and without Mp activity. During hospitalization, among 
Mp PCR-positive children, length of stay was similar between children who did (median, 3 
[IQR, 2–5] days) and did not (median, 2 days [IQR, 1–3] days) receive an inpatient 
antibiotic with Mp activity (P = .6).
Codetections
Of the 178 (98%) Mp PCR-positive children who had specimens tested for both bacteria and 
viruses, 50 (28%) had a codetection; 46% of those with a codetection were <5 years old 
(Supplementary Table 2). Among Mp PCR-positive children, 48 (96%) had at least 1 viral 
codetection, 1 (2%) had a single bacterial codetection (S. pneumoniae), and 1 (2%) had both 
bacterial (S. pneumoniae) and viral (rhinovirus) codetections. When stratified by age, Mp 
PCR-positive children <5 years old were more likely than Mp PCR-negative children to have 
a codetection (65% vs 34%; P <.01), compared with children 5–9 years old (21% vs 67%; P 
<.01) and 10–17 years old (21% vs 56%; P <.01), Mp PCR-positive children were less likely 
than Mp PCR-negative children to have a codetection.
Multivariable Analyses
Variables independently associated with increased odds of Mp detection included age 10–17 
years and 5–9 years; clinical signs and symptoms of hilar lymphadenopathy, rales, headache, 
sore throat, or decreased breath sounds; antibiotic receipt ≤5 days before admission; and any 
codetection (Table 3). Wheeze, rhinorrhea, and chest pain, in addition to study site and ICU 
admission, were significantly less likely to be associated with Mp detection (Table 3).
Macrolide Susceptibility
Of the Mp PCR-positive specimens, 176 (97%) were positive upon repeat PCR testing at the 
CDC; Mp isolates were recovered from 169 (96%) specimens by culture, and 6 (4%) isolates 
were macrolide resistant. All 6 (100%) children with macrolide-resistant Mp isolates were 
non-Hispanic white; 5 (83%) were >5 years old, and 4 (67%) were male. Four (67%) 
patients with a macrolide-resistant isolate had received a macrolide before admission; 2 
between 0 and 5 days before admission and 2 between 6 and 15 days before admission. Of 
the 6 macrolide-resistant isolates, 3 (50%) were from Memphis, 2 (33%) were from 
Nashville, and 1 (17%) was from Salt Lake City. There were no significant differences in 
symptoms and outcomes between children with and without macrolide-resistant Mp.
DISCUSSION
In this large US multicenter active surveillance study with prospective enrollment and 
systematic microbiological testing among children hospitalized with CAP, Mp was the most 
commonly detected bacteria and most prevalent in school-aged children ≥5 years old. 
Although there were no deaths and few patients required mechanical ventilation, 1 in 10 
hospitalized children with Mp PCR-positive CAP were admitted to the ICU. Clinically, Mp 
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CAP children had nonspecific symptoms that were not sufficiently distinctive to differentiate 
CAP due to Mp from other etiologies. The clinical symptoms associated with Mp CAP on 
multivariable analysis are similar to those observed with respiratory viral illnesses, including 
influenza infection [22, 23]. In addition, the clinical features independently associated with 
Mp detection, such as rales, have historically been associated with typical bacterial 
infections [22].
Respiratory viral PCR panels are increasingly being used for clinical purposes with US Food 
and Drug Administration-approved and validated assays for Mp. However, their use is not 
yet widespread [14, 24, 25]. PCR is the current gold standard for diagnosis of Mp, due to its 
superior specificity compared to serology [17–19, 26–28]. A 2004 US pediatric population-
based study reported a Mp prevalence of 14% among 154 children hospitalized with CAP 
using serology (positive if enzyme-linked immunosorbent assay immunoglobulin M was 
≥1:10, or ≥4-fold rise in immunoglobulin G titer) [29]. However, among the 21 children who 
were seropositive and who had a corresponding NP/OP swab collected within 24 hours of 
admission, only 12 (57%) had Mp detected by PCR [26]. While Mycoplasma detection in 
asymptomatic children has been previously reported (21.2% in the Netherlands) [30], Mp 
was infrequently detected among our convenience sample of asymptomatic controls (0.6%), 
suggesting that Mp is the likely cause of illness when detected by PCR (Supplementary 
Materials). The differences in the study results may be a result of differences in control 
definitions, temporal or geographical variation in Mp activity, or the length of the study (24 
months vs 16 months, respectively).
Our results indicate that Mp was the most commonly detected bacteria among children 
hospitalized with pneumonia and those symptoms, signs, and radiographic findings would 
not help to distinguish Mp from viral pneumonia; therefore, clinicians may not have a 
reliable way to suspect Mp infection without diagnostic testing. In our study, results of 
assays done only for research purposes, including Mp tests, were not available to guide 
clinical decisions. We did not identify differences in length of stay between Mp patients who 
did and did not receive an antibiotic with activity against Mp. This finding is also consistent 
with another study that compared the effectiveness of empirical β-lactam monotherapy vs β-
lactam plus macrolide combination therapy using data from the EPIC study; there were no 
differences in length of stay, rehospitalizations, or recovery at follow-up, including among 
the subgroup of children with Mp [31]. The EPIC study, however, was observational and 
limited to hospitalized children. Thus, there is a need for high-quality randomized trials to 
definitively address the impact of antibiotic therapy with Mp activity on CAP patient 
outcomes [32].
Macrolide-resistant Mp isolates have been described in the United States (3%−10%) and 
several other countries, particularly in Europe and Asia [33–35]. We identified very few (6 
[4%]) macrolide-resistant Mp isolates and thus were not able to adequately assess factors or 
outcomes associated with resistance. However, continued vigilance is needed to better 
understand the extent and clinical implications of macrolide-resistant Mp infections.
Our study has several limitations. By including Mp with codetections, some of the 
symptoms, especially among those <5 years old, could be attributable to other pathogens. In 
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addition, test sensitivity may be variable between detection assays for some pathogens, 
especially for bacteria. Another possible limitation is that some patients received antibiotics 
with Mp activity before NP/OP collection, which may have affected the detection of Mp. 
However, Mp was detected by PCR in 11% of the children hospitalized with CAP who 
received an antibiotic with Mp activity before admission [36]. Finally, our findings may not 
be representative of Mp CAP in the United States, because the 3 study sites were academic 
centers in urban areas, and 45% of Mp cases were identified at a single site (Salt Lake City, 
Utah).
In conclusion, Mp was the most commonly detected bacterial pathogen among hospitalized 
children <18 years old with CAP who underwent NP/OP PCR testing [15]. The prevalence 
was highest among children 10–17 years old, indicating the significant role of Mp among 
older children. Although Mp illness is often mild and self-limited [6], in this study 12% of 
hospitalized children with Mp were admitted to the ICU. Increasing access to Mp PCR could 
facilitate prompt diagnosis resulting in more targeted and appropriate treatment. In addition, 
there is a need to understand and define the burden of disease of Mp in the community that 
is not only causing pneumonia. This can be addressed by systematic surveillance for Mp 
infection as a cause of CAP and other clinical syndromes, which could further facilitate case 
and outbreak identification, better characterize the prevalence of macrolide resistance, and 
inform treatment and infection prevention guidance.
Supplementary Material
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Acknowledgments.
We thank the children and families who graciously consented to participate in the Etiology of Pneumonia in the 
Community study.
Financial support. This work was supported by the Influenza Division of the National Center for Immunizations 
and Respiratory Diseases at the CDC through cooperative agreements with each study site and was based on a 
competitive research funding opportunity.
References
1. Bitnun A, Ford-Jones EL, Petric M, et al. Acute childhood encephalitis and Mycoplasma 
pneumoniae. Clin Infect Dis 2001; 32:1674–84. [PubMed: 11360206] 
2. Daxboeck F, Blacky A, Seidl R, Krause R, Assadian O. Diagnosis, treatment, and prognosis of 
Mycoplasma pneumoniae childhood encephalitis: systematic review of 58 cases. J Child Neurol 
2004; 19:865–71. [PubMed: 15658791] 
3. Meyer Sauteur PM, Streuli JC, Iff T, Goetschel P. Mycoplasma pneumoniae-associated encephalitis 
in childhood-nervous system disorder during or after a respiratory tract infection. Klin Padiatr 2011; 
223:209–13. [PubMed: 21509704] 
4. Meyer Sauteur PM, Goetschel P, Lautenschlager S. Mycoplasma pneumoniae and mucositis—part 
of the Stevens-Johnson syndrome spectrum. J Dtsch Dermatol Ges 2012; 10:740–6. [PubMed: 
22672205] 
5. Olson D, Watkins LK, Demirjian A, et al. Outbreak of Mycoplasma pneumoniae-associated 
Stevens-Johnson syndrome. Pediatrics 2015; 136:e386–94. [PubMed: 26216320] 
6. Waites KB, Talkington DF. Mycoplasma pneumoniae and its role as a human pathogen. Clin 
Microbiol Rev 2004; 17:697–728, table of contents. [PubMed: 15489344] 
Kutty et al. Page 8
Clin Infect Dis. Author manuscript; available in PMC 2019 June 06.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
7. Watkins LKF, Olson D, Diaz MH, et al. Epidemiology and molecular characteristics of Mycoplasma 
pneumoniae during an outbreak of M. pneumoniae-associated Stevens-Johnson syndrome. Pediatr 
Infect Dis J 2017; 36:564–71. [PubMed: 28060039] 
8. Foy HM, Grayston JT, Kenny GE, Alexander ER, McMahan R. Epidemiology of Mycoplasma 
pneumoniae infection in families. JAMA 1966; 197:859–66. [PubMed: 5952772] 
9. Foy HM, Alexander ER. Mycoplasma pneumoniae infections in childhood. Adv Pediatr 1969; 
16:301–23. [PubMed: 4981080] 
10. Fernald GW, Clyde WA Jr. Epidemic pneumonia in university students. J Adolesc Health Care 
1989; 10:520–6. [PubMed: 2514160] 
11. Waites KB. New concepts of Mycoplasma pneumoniae infections in children. Pediatr Pulmonol 
2003; 36:267–78. [PubMed: 12950038] 
12. Broome CV, LaVenture M, Kaye HS, et al. An explosive outbreak of Mycoplasma pneumoniae 
infection in a summer camp. Pediatrics 1980; 66:884–8. [PubMed: 6779260] 
13. Sterner G, de Hevesy G, Tunevall G, Wolontis S. Acute respiratory illness with Mycoplasma 
pneumoniae. An outbreak in a home for children. Acta Paediatr Scand 1966; 55:280–6. [PubMed: 
4289665] 
14. Winchell JM. Mycoplasma pneumoniae—a national public health perspective. Curr Pediatr Rev 
2013; 9:324–33.
15. Jain S, Williams DJ, Arnold SR, et al.; CDC EPIC Study Team. Community- acquired pneumonia 
requiring hospitalization among U.S. children. N Engl J Med 2015; 372:835–45. [PubMed: 
25714161] 
16. Cherian T, Mulholland EK, Carlin JB, et al. Standardized interpretation of paediatric chest 
radiographs for the diagnosis of pneumonia in epidemiological studies. Bull World Health Organ 
2005; 83:353–9. [PubMed: 15976876] 
17. Diaz MH, Benitez AJ, Cross KE, et al. Molecular detection and characterization of Mycoplasma 
pneumoniae among patients hospitalized with community-acquired pneumonia in the United 
States. Open Forum Infect Dis 2015; 2:ofv106.
18. Wolff BJ, Thacker WL, Schwartz SB, Winchell JM. Detection of macrolide resistance in 
Mycoplasma pneumoniae by real-time PCR and high-resolution melt analysis. Antimicrob Agents 
Chemother 2008; 52:3542–9. [PubMed: 18644962] 
19. Diaz MH, Benitez AJ, Winchell JM. Investigations of Mycoplasma pneumoniae infections in the 
United States: trends in molecular typing and macrolide resistance from 2006 to 2013. J Clin 
Microbiol 2015; 53:124–30. [PubMed: 25355769] 
20. Matsuoka M, Narita M, Okazaki N, et al. Characterization and molecular analysis of macrolide-
resistant Mycoplasma pneumoniae clinical isolates obtained in Japan. Antimicrob Agents 
Chemother 2004; 48:4624–30. [PubMed: 15561835] 
21. Bébéar C, Pereyre S, Peuchant O. Mycoplasma pneumoniae: susceptibility and resistance to 
antibiotics. Future Microbiol 2011; 6:423–31. [PubMed: 21526943] 
22. Musher DM, Thorner AR. Community-acquired pneumonia. N Engl J Med 2014; 371:1619–28. 
[PubMed: 25337751] 
23. Harper SA, Bradley JS, Englund JA, et al.; Expert Panel of the Infectious Diseases Society of 
America. Seasonal influenza in adults and children—diagnosis, treatment, chemoprophylaxis, and 
institutional outbreak management: clinical practice guidelines of the Infectious Diseases Society 
of America. Clin Infect Dis 2009; 48:1003–32. [PubMed: 19281331] 
24. Babady NE. The FilmArray respiratory panel: an automated, broadly multiplexed molecular test 
for the rapid and accurate detection of respiratory pathogens. Expert Rev Mol Diagn 2013; 
13:779–88. [PubMed: 24151847] 
25. Ratliff AE, Duffy LB, Waites KB. Comparison of the Illumigene Mycoplasma DNA amplification 
assay and culture for detection of Mycoplasma pneumoniae. J Clin Microbiol 2014; 52:1060–3. 
[PubMed: 24430454] 
26. Michelow IC, Olsen K, Lozano J, Duffy LB, McCracken GH, Hardy RD. Diagnostic utility and 
clinical significance of naso- and oropharyngeal samples used in a PCR assay to diagnose 
Mycoplasma pneumoniae infection in children with community-acquired pneumonia. J Clin 
Microbiol 2004; 42:3339–41. [PubMed: 15243111] 
Kutty et al. Page 9
Clin Infect Dis. Author manuscript; available in PMC 2019 June 06.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
27. Beersma MF, Dirven K, van Dam AP, Templeton KE, Claas EC, Goossens H. Evaluation of 12 
commercial tests and the complement fixation test for Mycoplasma pneumoniae-specific 
immunoglobulin G (IgG) and IgM antibodies, with PCR used as the “gold standard”. J Clin 
Microbiol 2005; 43:2277–85. [PubMed: 15872256] 
28. Dorigo-Zetsma JW, Zaat SA, Wertheim-van Dillen PM, et al. Comparison of PCR, culture, and 
serological tests for diagnosis of Mycoplasma pneumoniae respiratory tract infection in children. J 
Clin Microbiol 1999; 37:14–7. [PubMed: 9854056] 
29. Michelow IC, Olsen K, Lozano J, et al. Epidemiology and clinical characteristics of community-
acquired pneumonia in hospitalized children. Pediatrics 2004; 113:701–7. [PubMed: 15060215] 
30. Spuesens EB, Fraaij PL, Visser EG, et al. Carriage of Mycoplasma pneumoniae in the upper 
respiratory tract of symptomatic and asymptomatic children: an observational study. PLoS Med 
2013; 10:e1001444.
31. Williams DJ, Edwards KM, Self WH, et al. Effectiveness of ß-lactam monotherapy vs macrolide 
combination therapy for children hospitalized with pneumonia. JAMA Pediatr 2017; 171:1184–91. 
[PubMed: 29084336] 
32. Biondi E, McCulloh R, Alverson B, Klein A, Dixon A, Ralston S. Treatment of mycoplasma 
pneumonia: a systematic review. Pediatrics 2014; 133:1081–90. [PubMed: 24864174] 
33. Li X, Atkinson TP, Hagood J, Makris C, Duffy LB, Waites KB. Emerging macrolide resistance in 
Mycoplasma pneumoniae in children: detection and characterization of resistant isolates. Pediatr 
Infect Dis J 2009; 28:693–6. [PubMed: 19633515] 
34. Yamada M, Buller R, Bledsoe S, Storch GA. Rising rates of macrolide-resistant Mycoplasma 
pneumoniae in the central United States. Pediatr Infect Dis J 2012; 31:409–0. [PubMed: 
22209916] 
35. Critchley IA, Jones ME, Heinze PD, et al. In vitro activity of levofloxacin against contemporary 
clinical isolates of Legionella pneumophila, Mycoplasma pneumoniae and Chlamydia pneumoniae 
from North America and Europe. Clin Microbiol Infect 2002; 8:214–21. [PubMed: 12047413] 
36. Harris AM, Bramley AM, Jain S, et al. Influence of antibiotics on the detection of bacteria by 
culture-based and culture-independent diagnostic tests in patients hospitalized with community-
acquired pneumonia. Open Forum Infect Dis 2017; 4:ofx014.
Kutty et al. Page 10
Clin Infect Dis. Author manuscript; available in PMC 2019 June 06.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 1. 
Prevalence of Mycoplasma pneumoniae among children hospitalized for community-
acquired pneumonia who underwent real-time polymerase chain reaction (PCR) testing, by 
time and study site, January 2010–June 2012. Prevalence = (number of M. pneumoniae 
PCR-positive nasopharyngeal/oropharyngeal [NP/OP] specimens/ total number of NP/OP 
specimens that underwent PCR testing) × 100.
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Table 2.
Clinical Features Among Children Hospitalized for Community-acquired Pneumonia With and Without 
Mycoplasma pneumoniae (N = 2254)
Characteristic
Mycoplasma pneumoniae
PCR-Positivea (n = 182)
Mycoplasma pneumoniae
PCR-Negativeb (n = 2072) Unadjusted OR P Value
Clinical presentationc
 Fever/feverish 174 (96) 1885 (91)     2.2 (1.01–4.5) .03
 Cough 174 (96) 1960 (95) 1.2 (.6–2.6) .6
 Fatigue 142 (78) 1425 (63)   1.6 (1.1–2.3) <.01
 Lack of appetite 141 (77) 1542 (68) 1.2 (.8–1.7) .4
 Dyspnea 121 (67) 1479 (71) 0.8 (.6–1.1) .2
 Chills 102 (56)  729 (35)    2.3 (1.7–3.2) <.01
 Headache  87 (48)  425 (21)    3.5 (2.6–4.8) <.01
 Sore throat  86 (47)  582 (28)    2.3 (1.7–3.1) <.01
 Wheezing  82 (45) 1303 (63) 0.5 (.4–.7) <.01
 Runny nose  80 (44) 1484 (72) 0.3 (.2–.4) <.01
 Abdominal pain  76 (42)  427 (21)     2.7 (2.0–3.8) <.01
 Diarrhea  64 (35)  626 (30) 1.3 (.9–1.7) .2
 Myalgia  63 (35) 366 (18)     2.5 (1.8–3.4) <.01
 Chest pain  50 (27)  436 (21)     1.4 (1.01–2.0) .04
 Chest retraction  46 (25)  953 (46) 0.4 (.3–.6) <.01
Underlying condition
 Any condition (≥1 condition)  83 (46) 1066 (51) 0.8 (.6–1.1) .1
 Asthma/reactive airway disease  55 (30)  700 (34) 0.9 (.6–1.2) .3
 Preterm birthd 6/21 (29)          201/988 (20) 1.6 (.6–4.1) .4e
 Congenital heart disease 14 (8) 147 (7) 1.1 (.6–1.9) .8
 Neurological disorder 11 (6) 180 (9) 0.7 (.4–1.3) .2
 Chromosomal disorder 16 (9) 112 (5)   1.7 (1.0–2.9) .06
Examination findings at presentation
 Decreased breath sounds 114 (63) 842 (41) 2.4 (1.8–3.3) <.01
 Rales 110 (60) 814 (39) 2.4 (1.7–3.2) <.01
 Tachypneaf  78 (43) 740 (36) 1.4 (1.0–1.8) .05
 Documented feverg  67 (36) 1003 (48)     0.6 (.5–.8) <.01
 Hypoxiah  77 (42) 768 (37) 1.3 (.9–1.7) .2
 Chest indrawing  55 (30) 1172 (57) 0.3 (.2–.5) <.01
 Rhonchi  49 (27) 855 (41) 0.5 (.4–.7) <.01
 Wheezing  48 (26) 875 (42) 0.5 (.3–.7) <.01
Radiographic findingsi
 Consolidation 108 (59)j 1219 (59) 1.0 (.8–1.4) .9
 Single lobar infiltrate  59 (32) 534 (26) 1.4 (1.0–2.0) .05
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Characteristic
Mycoplasma pneumoniae
PCR-Positivea (n = 182)
Mycoplasma pneumoniae
PCR-Negativeb (n = 2072) Unadjusted OR P Value
 Multilobar infiltrates  42 (23) 573 (28) 0.8 (.5–1.1) .2
 Multilobar infiltrates (unilateral)  20 (11) 155 (7) 1.5 (.9–2.5) .09
 Multilobar infiltrates (bilateral)  22 (12) 420 (20) 0.5 (.3–.9) <.01
 Pleural effusion  48 (26) 244 (12)    2.7 (1.9–3.8) <.01
 Complicated bronchiolitis  21 (12) 610 (29) 0.3 (.2–.5) <.01
 Hilar lymphadenopathy  18 (10) 114 (6)    1.9 (1.1–3.2) .02
Laboratory findings
 Abnormal WBC countk
  Leukopenia 2/160 (1) 98/1074 (6) 0.2 (.05–.8) .03
  Leukocytosis 40/160 (25) 463/1074 (27) 0.9 (.6–1.3) .6
 Abnormal platelet countl
  Thrombocytopenia 6/159 (4) 73/1681 (4) 0.9 (.4–2.0) .7
  Thrombocytosis 15/159 (9) 182/1681 (11) 0.9 (.5–1.5) .6
 Hyponatremiam 12/110 (11) 125/1352 (9) 1.2 (.6–2.3) .6
Severity of illness
 ICU admission        21 (12) 431 (21) 0.5 (.3–.8) <.01
 Invasive mechanical ventilation        3 (2) 143 (7)   0.2 (.07–.7) <.01
 Length of stay, d, median (IQR)           2 (2–4)          3 (2–4) .1n
Antibiotics
 Receipt of an outpatient antibiotic      90 (50)       482 (23)   3.2 (2.4–4.4) <.01
 Receipt of antibiotics prior to admission within 5 
d      64 (35)       338 (16)   2.8 (2.0–3.9) <.01
  Penicillins  44/64 (69) 173/338 (51) Reference
  Cephalosporins  13/64 (20) 101/338 (30) 0.5 (.3–1.0) .05
  Macrolides   7/64 (11)   56/338 (17) 0.5 (.2–1.2) .1
 Inpatient antibiotics      175 (96)        1794 (87)   3.9 (1.8–8.3) <.01
  Macrolideso  75/175 (43) 351/1794 (20)   2.3 (1.6–3.3) <.01
  Penicillins  72/175 (41) 776/1794 (43) Reference
  Cephalosporin  27/175 (15) 639/1794 (36) 0.5 (.3–.7) <.01
Data are presented as No. (%) unless otherwise indicated.
Abbreviations: CI, confidence interval; ICU, intensive care unit; IQR, interquartile range; OR, odds ratio; PCR, polymerase chain reaction; WBC, 
white blood cell.
a
Radiographically confirmed community-acquired pneumonia (CAP) in a patient enrolled in the Etiology of Pneumonia in the Community (EPIC) 
study with a positive Mycoplasma pneumoniae PCR result.
b
Radiographically confirmed CAP in a patient enrolled in the EPIC study with a negative Mycoplasma pneumoniae PCR result.
cClinical presentation is based on patient history.
dOnly for those children <2 years of age.
e
Fisher exact test.
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f
Tachypnea: For children <2 months: >60 breaths/minute; 2 months to <12 months: >50 breaths/minute; 12 months to 5 years: >40 breaths/minute; 
>5 years: >25 breaths/minute were considered as abnormal.
g
Temperature ≥38.0°C or ≥100.4°F.
h
Hypoxia: Oxygen saturation rate <92% on admission using pulse oximetry on room air or requirement of supplemental oxygen at the time of 
presentation.
i
The radiographic findings are not mutually exclusive and could overlap.
j
Thirty-two (30%) of the Mycoplasma pneumoniae CAP children with a consolidation had a codetection.
k
For children <5 years old, WBC count >15 000/μL or <5500/μL and for children ≥5 years old, WBC count >11 000/μL or <3000/μL was 
considered abnormal.
l
Platelet count of <150 000 cells/μL or >500 000 cells/μL was considered abnormal.
m
For children <1 year of age, serum sodium <130 U/L and for those >1 year of age, serum levels of <135 U/L were considered abnormal.
nWilcoxon 2-sample test.
o
Macrolides received as inpatient treatment: azithromycin 74 (99%); clarithromycin: 1 (1%).
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Table 3.
Characteristicsa Associated With Mycoplasma pneumoniae Among US Children (<18 Years) Hospitalized for 
Community-acquired Pneumonia in Multivariate Analysis
Characteristic
Adjusted OR
(95% CI) P Value
Age, y
 2–4 Reference group
 5–9  6.4 (3.4–12.1) <.01
 10–17 10.7 (5.4–21.1) <.01
Hilar lymphadenopathy 3.1 (1.6–5.8) <.01
Receipt of antibiotics prior
  to admission within 5 d
2.3 (1.5–3.5) <.01
Rales 2.2 (1.5–3.2) <0.01
Codetected pathogens 2.1 (1.4–3.3) <.01
Headache   1.6 (1.04–2.5) .03
Sore throat  1.6 (1.1–2.3) .03
Decreased breath sounds    1.5 (1.01–2.2) .04
Wheezing (symptom)     0.6 (.4–.9) <.01
Runny nose     0.6 (.4–.8) <.01
Study site (Salt Lake City)     0.5 (.4–.8) <.01
Chest pain     0.4 (.3–.7) <.01
Abbreviations: CI, confidence interval; OR, odds ratio.
a
 For this analysis, only children who had specimens tested for both bacteria and viruses were included. Variables that were tested in the model but 
did not reach significance: sex, clinical presentation of fever/feverish, fatigue, chills, abdominal pain, myalgia, dyspnea, examination findings on 
presentation: hypoxia, rhonchi, wheezing, chest indrawing, tachypnea, chest retraction; radiographic findings: single and multiple lobar infiltrate, 
pleural effusion; comorbid condition: chromosomal disorder; household size; interaction between age and codetection.
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